

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Report: cder_iqp_wp022 (Report 1 of 4)

Request ID: cder_iqp_wp022

Request Description: In this report, we described COVID-19 therapeutic treatment and death among patients who were hospitalized with COVID-19 and among patients with severe COVID-19, stratified by racial and ethnic group. In addition to describing these groups overall, we also described the subset of each group with evidence of vaccination against COVID-19. This is report 1 of 4. Report 1 includes data from January 1, 2021 - April 30, 2021. Report 2 includes data from May 1, 2021 - August 31, 2021. Report 3 includes data from September 1, 2021 - December 31, 2021. Report 4 includes data from January 1, 2022 - April 30, 2022.

Data Source: We ran this query on June 21, 2022. This query contains data from 36 health care organizations (HCOs), provided through the TriNetX Live[™] platform in the USA Network with No Shift from January 1, 2021 to April 30, 2021.

TriNetX aggregates electronic health record (EHR) systems data from its partner HCOs to create queryable datasets. TriNetX datasets primarily comprise clinical patient data such as demographics, diagnoses, procedures, labs, and medications. The USA Network with No Shift contains HCOs that do not date shift their data. For more information on the TriNetX Live[™] platform and the TriNetX data visit their website here: https://trinetx.com/

Study Design: We identified individuals of different racial and ethnic groups with evidence of hospitalized COVID-19 and severe COVID-19, overall and among those with a history of vaccination against COVID-19. This was done using the Query Builder module in the TriNetX Live™ platform. We additionally characterized the demographic and geographic distribution of our cohorts using the Explore Cohort module. We further utilized the Compare Outcomes Analytics module to count the number of patients with a death record or evidence of various COVID-19 therapeutic treatments, including remdesivir, systemic glucocorticoids, baricitinib, COVID-19 convalescent plasma, IL-1 inhibitors, tocilizumab, bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab.

<u>Cohort Definition</u>: Our cohorts of interest in this request were hospitalized COVID-19 and severe COVID-19. We defined hospitalized COVID-19 as evidence of a COVID-19 diagnosis or positive lab result with a record of an inpatient visit within three days before or after the COVID-19 record. We defined severe COVID-19 as evidence of a COVID-19 diagnosis or positive lab result with evidence of either an intensive care unit (ICU) encounter, extracorporeal membrane oxygenation (ECMO), or mechanical ventilation within seven days after the COVID-19 record. For cohorts with a history of COVID-19 vaccination, we required patients to have evidence of a COVID-19 vaccine any time prior to their COVID-19 record. For outcome evaluation, we defined our index date as the first day in which patients fulfilled all relevant cohort-defining events. Please see Appendix A for a list of codes used to define the cohorts in this request.

<u>Cohort Eligibility Criteria</u>: For each of our racial and ethnic demographic cohorts of interest, we defined the population by including an "ungrouped" demographic term for race or ethnicity in all Query Builder queries. We separately assessed the following racial and ethnic cohorts:

1) Overall

2) American Indian or Alaska Native OR Native Hawaiian or Other Pacific Islander

3) Asian

4) Black or African American

5) White

6) Unknown race or ethnicity (defined as patients "cannot have" any other demographic race or ethnicity term)

- 7) Hispanic/Latino
- 8) Non-Hispanic/Latino



Overview for Report: cder_iqp_wp022 (Report 1 of 4)

Outcomes of Interest: Our outcomes of interest in this request were death and the following grouped COVID-19 treatments: 1) remdesivir or systemic glucocorticoids, 2) baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors, 3) tocilizumab, and 4) bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab. We utilized the "Measures of Association" metric in the Compare Outcomes Analytics module to determine the number of patients with each outcome of interest. For the death outcome, we looked for evidence of a death record in the 0-30 days following the cohort-defining index criteria. For the COVID-19 treatment outcomes, we looked for evidence of the treatment of interest in the 0-14 days following index. We defined these COVID-19 treatments using RxNorm medication terms, Healthcare Common Procedure Coding System (HCPCS), and International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes. Please see Appendix B for a list of RxNorm terms and procedure codes used to define outcomes in this request.

Please see Appendices C-E for the specifications of parameters used in this request and design diagrams.

Limitations: Algorithms used to define cohorts and outcomes and mapping of source data to the data model are imperfect and susceptible to misclassification. Additionally, EHR data in the US lacks longitudinality. The information before or after patients' healthcare encounters could be missing, especially if patient care was administered across different HCOs that might not participate in the TriNetX USA network. We are unable to determine if absence of evidence of a condition implies a true absence of a condition or if the condition was not observed in the data. Therefore, data should be interpreted with these limitations in mind.

All counts provided through the TriNetX Live™ platform are rounded up to the nearest 10 to protect patient privacy. This rounding affects error, especially as sample sizes decrease. Error due to rounding can range from <0.09% when sample sizes are

>10,000 to nearly 20% as sample sizes drop. Thus, all estimates should be interpreted as ranges, and small sample sizes should be interpreted with caution.

<u>Notes:</u> We ran this query on June 21, 2022. A re-run of this query for the same query period in the future may not yield the same results owing to the dynamic nature of the TriNetX Live[™] network.

Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's querying in the TriNetX platform, please refer to the Sentinel Website (https://www.sentinelinitiative.org/methods-data-tools/methods/trinetx-rapid-querying).



	Table of Contents
Glossary	Terms for Analyses Using TriNetX Live™ Platform
Table 1	COVID-19 Therapeutics and Death Among Hospitalized Patients with COVID-19 and Patients with Severe COVID- 19 from January 1, 2021 - April 30, 2021, by Vaccination History
Figure 1a	Demographics Among Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1b	Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1c	Demographics Among Asian Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1d	Demographics Among Black or African American Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1e	Demographics Among White Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1f	Demographics Among Unknown Race or Unknown Ethnicity Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1g	Demographics Among Hispanic/Latino Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 1h	Demographics Among Non-Hispanic/Latino Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021
Figure 2a	Demographics Among Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2b	Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2c	Demographics Among Asian Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2d	Demographics Among Black or African American Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2e	Demographics Among White Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2f	Demographics Among Unknown Race or Unknown Ethnicity Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2g	Demographics Among Hispanic/Latino Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 2h	Demographics Among Non-Hispanic/Latino Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021
Figure 3a	Demographics Among Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021
Figure 3b	Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021
Figure 3c	Demographics Among Asian Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021



Table of Contents							
Figure 3d	Demographics Among Black or African American Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021						
Figure 3e Figure 3f	Demographics Among White Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021 Demographics Among Unknown Race or Unknown Ethnicity Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021						
Figure 3g	Demographics Among Hispanic/Latino Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021						
Figure 3h	Demographics Among Non-Hispanic/Latino Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021						
Figure 4a	Demographics Among Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4b	Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4c	Demographics Among Asian Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4d	Demographics Among Black or African American Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4e	Demographics Among White Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4f	Demographics Among Unknown Race or Unknown Ethnicity Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4g	Demographics Among Hispanic/Latino Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 4h	Demographics Among Non-Hispanic/Latino Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021						
Figure 5a	Geographic Distribution of Patients Hospitalized with COVID-19 from January 1, 2021 to April 30, 2021, by Race/Ethnicity						
Figure 5b	Geographic Distribution of Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 to April 30, 2021, by Race/Ethnicity						
Figure 5c	Geographic Distribution of Patients with Severe COVID-19 from January 1, 2021 to April 30, 2021, by Race/Ethnicity						
Figure 5d	Geographic Distribution of Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 to April 30, 2021, by Race/Ethnicity						
Appendix A	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT), and International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) Procedure Codes, RxNorm Medication Codes, TriNetX Laboratory (TNX:LAB) Codes, and Visit Terms Used to Define Cohorts in this Request						



	Table of Contents						
Appendix B	List of Healthcare Common Procedure Coding System (HCPCS) and International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) Procedure Codes, and RxNorm Medication Codes Used to Define Outcomes in this Request						
Appendix C	Specifications Defining Query Builder Cohorts in this Request						
Appendix D	Specifications Defining Analytics Modules in this Request						
Appendix E	Design Diagrams of Cohort Entry Requirements						



Glossary of Terms for Analyses Using TriNetX Live™ Platform*

Characteristic - A medical fact (e.g., diagnosis, procedure, lab result) that occurred on or before the cohort-defining index event.

Explore Cohort - A description module on the TriNetX platform that presents a clinical profile of patients in a given cohort. Patient counts are rounded up to the nearest 10 before percentages are calculated, so the sum each of the values in one category may not total to 100%.

Date Shifting - A data obfuscation technique that some HCOs use to preserve patient privacy. Date shifting entails assigning each patient a random number of days (eg, -365 to +365 days) and consistently adjusting each of their dates by that number of days, thus maintaining temporal relationships between records within a single patient.

Fact - (Medical Fact) A unit of utilization that represents a medical observation on a patient (e.g., diagnosis, procedure, clinical observation).

Filter - A method of limiting terms included in queries to a specific subset of data. Filters include age at time of event, data source (electronic health record or natural language processing); brand name, route, and strength for medication terms; occurrence (first or most recent) for lab terms; and priority for diagnosis and procedure terms.

Group - A series of codes and terms defined with Boolean logic that are used to create a query cohort. For each group, users have the ability to specified time periods of interest, and the number of instances that the group must occur for cohort entry.

Subgroup - Within a group, additional subgroups can be specified to define temporal relationships between the terms in the subgroup (e.g., terms in subgroup B must occur within 5 days after terms in subgroup A). Users can require that these temporal constraints be applied to the 1) first, 2) last, or 3) any instance of each subgroup.

Health Care Organization (HCO) - Organizations that contribute electronic healthcare record data to the TriNetX data networks. HCOs include academic institutions and community health provider systems and a single HCO may contain one or more individual sites or facilities.

Index - The first date when a patient meets all of the cohort-defining criteria. In Analytics modules, the index can be defined as the date when a patient meets all of the cohort criteria, or only one specific group's criteria.

Module - A subsection of the TriNetX platform that performs a distinct functionality. Cohorts are created using the Query Builder module. Descriptive modules include Healthcare Organizations, Explore Cohorts, Rate of Arrival, Summary Statistics, and Analyze Criteria. Advanced analytic modules include Analyze Outcomes, Compare Outcomes, Compare Cohorts, Treatment Pathways, and Incidence and Prevalence.

Network - An aggregation of HCOs contributing data to the platform. Multiple networks are available for querying on the platform; the different networks represent subsets of HCOs organized by date-shifting practices or availability of downloadable datasets.

Outcome - A medical fact (e.g., diagnosis, procedure, lab result) that occurred on or after the cohort-defining index event.

Query - In the TriNetX platform, a query is a distinct cohort with a unique set of terms and logic. Query cohorts are created using the Query Builder platform module.

Risk - In Advanced Analytics modules, risk refers to the percentage of patients in each cohort with the specified outcome of interest.

Priority - An indication whether the code was the condition that the provider spent the most time evaluating or treating during a visit. Possible values include primary, secondary, or unknown.

Term - The codes used to specify patient cohort criteria in a query. Code options include diagnoses, procedures, medications, labs, demographics, genomics, and visits. Terms can be linked together using and/or Boolean logic. TriNetX also creates terms that group together multiple medical codes into single clinical concepts.



Cannot Have Term - A category of terms within a query group that patients must not have evidence of to be included in the cohort.

Must Have Term - A category of terms within a query group that patients must have evidence of to be included in the cohort.

Time Constraint - used to define time periods of interest for each group within a query. Time constraints can be defined relative to the date the query was run (e.g., any time before today), or defined based on specific dates (e.g., January 1, 2015 to September 30, 2020).

Treatment Pathway - In Advanced Analytics modules, the Treatment Pathways module returns the order in which patients received treatment and the prevalence of treatments, including combination of medications, following an index event.

TriNetX Codes - For commonly used laboratory terms, TriNetX aggregates Logical Observation Identifiers Names and Codes (LOINC) laboratory codes at a clinically significant level to new queryable TNX:LAB terms.

Visit - A type of term used to specify the type of medical encounter or facility where the encounter was recorded. Visit terms are derived by TriNetX from the source data. Visits are recorded separately from the codes or labs that occurred during the encounter; care settings are not attached to individual codes. Values for visit terms include: ambulatory, emergency, field, home health, inpatient encounter, inpatient acute, inpatient non-acute, laboratory, observation, pharmacy, pre-admission, short stay, virtual, and unknown.

*all terms may not be used in this report



Table 1. COVID-19 Therapeutics and Death Among Hospitalized Patients with COVID-19 and Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021, by Vaccination History^{1,2}

	Hospital	ized Patie	nts with C	OVID-19	Patier	nts with S	evere CO\	/ID-19
	Ove	Overall Vaccinat		nated	Ove	erall	Vacci	inated
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Patients of Any Race	72,600	100%	1,460	100%	11,770	100%	230	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	46,870	64.6%	800	54.8%	8,880	75.4%	170	73.9%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	4,200	5.8%	50	3.4%	930	7.9%	20	8.7%
Tocilizumab	1,300	1.8%	40	2.7%	630	5.4%	20	8.7%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	390	0.5%	20	1.4%	30	0.3%	10	4.3%
Death [0, 30 days]	5,200	7.2%	70	4.8%	3,800	32.3%	50	21.7%
Patients of American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Race*	370	100%	10	100%	90	100%	10	100%
Therapeutics [0, 14]								
Remdesivir or systemic glucocorticoids	290	78.4%			70	77.8%		
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	40	10.8%			10	11.1%		
Tocilizumab	20	5.4%			10	11.1%		
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	10	2.7%			0	0.0%		
Death [0, 30 days]	30	8.1%			30	33.3%		
Patients of Asian Race	2,850	100%	50	100%	390	100%	20	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	1,820	63.9%	30	60.0%	290	74.4%	20	100.0%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	170	6.0%	0	0.0%	30	7.7%	0	0.0%
Tocilizumab	50	1.8%	10	20.0%	30	7.7%	10	50.0%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	10	0.4%	10	20.0%	0	0.0%	0	0.0%
Death [0, 30 days]	110	3.9%	10	20.0%	90	23.1%	10	50.0%
Patients of Black or African American Race	14,220	100%	290	100%	2,340	100%	40	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	9,620	67.7%	180	62.1%	1,800	76.9%	30	75.0%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	780	5.5%	20	6.9%	180	7.7%	10	25.0%
Tocilizumab	340	2.4%	10	3.4%	150	6.4%	10	25.0%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	80	0.6%	10	3.4%	20	0.9%	10	25.0%
Death [0, 30 days]	870	6.1%	20	6.9%	710	30.3%	10	25.0%



Table 1. COVID-19 Therapeutics and Death Among Hospitalized Patients with COVID-19 and Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021, by Vaccination History^{1,2}

	Hospital	ized Patie	nts with C	OVID-19	Patier	nts with So	evere CO	/ID-19
	Ove	Overall Vaccinated		Ove	erall	Vacci	nated	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Patients of White Race	48,010	100%	1,010	100%	7,920	100%	150	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	30,780	64.1%	530	52.5%	5,970	75.4%	110	73.3%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	2,810	5.9%	30	3.0%	620	7.8%	20	13.3%
Tocilizumab	720	1.5%	30	3.0%	380	4.8%	20	13.3%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	280	0.6%	10	1.0%	20	0.3%	10	6.7%
Death [0, 30 days]	3,870	8.1%	50	5.0%	2,710	34.2%	40	26.7%
Patients of Unknown Race or Unknown Ethnicity	9,650	100%	180	100%	2,030	100%	40	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	6,070	62.9%	100	55.6%	1,550	76.4%	30	75.0%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	600	6.2%	10	5.6%	190	9.4%	10	25.0%
Tocilizumab	230	2.4%	10	5.6%	140	6.9%	10	25.0%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	40	0.4%	0	0.0%	10	0.5%	0	0.0%
Death [0, 30 days]	590	6.1%	10	5.6%	640	31.5%	10	25.0%
Patients of Hispanic/Latino Ethnicity	11,280	100%	190	100%	1,420	100%	40	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	8,300	73.6%	110	57.9%	1,210	85.2%	30	75.0%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	870	7.7%	10	5.3%	160	11.3%	10	25.0%
Tocilizumab	300	2.7%	10	5.3%	130	9.2%	10	25.0%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	60	0.5%	10	5.3%	10	0.7%	10	25.0%
Death [0, 30 days]	520	4.6%	20	10.5%	430	30.3%	20	50.0%
Patients of Non-Hispanic/Latino Ethnicity	57,720	100%	1,220	100%	9,120	100%	180	100%
Therapeutics [0, 14 days]								
Remdesivir or systemic glucocorticoids	36,320	62.9%	670	54.9%	6,710	73.6%	130	72.2%
Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors	3,110	5.4%	50	4.1%	660	7.2%	10	5.6%
Tocilizumab	950	1.6%	30	2.5%	450	4.9%	20	11.1%
Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab	310	0.5%	10	0.8%	20	0.2%	10	5.6%
Death [0, 30 days]	4,340	7.5%	60	4.9%	2,950	32.3%	40	22.2%

¹COVID-19 vaccination history assessed from (Ever, -1] days prior to index.

²All counts are rounded up to the nearest 10 to protect patient privacy and should be interpreted as ranges.

*Detailed information cannot be displayed when cohort size is between 1-10.






Figure 1a. Demographics Among Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
72,600	1	90	55	24








Figure 1b. Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021



Total Patients Minimum A	je Maximum Age	Mean Age	Standard Deviation
370	1 90	51	21








Figure 1c. Demographics Among Asian Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
2,850	1	90	56	23

Sex		Race
Male	52%	Asian 100%
Female	48%	American Indian or 0%
Unknown	0%	Black or African Am 0%
		White 0%
Ethnicity		Native Hawaiian or 0%
Not Hispanic or Lat	ti 97%	Unknown Race 0%
Jnknown Ethnicity	2%	
Hispanic or Latino	1%	






Figure 1d. Demographics Among Black or African American Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
14,220	1	90	52	23

Sex		Race
Female	55%	Black or African Am 100%
Male	45%	American Indian or 0%
Unknown	0%	Asian 0%
		White 0%
Ethnicity		Native Hawaiian or 0%
Not Hispanic or Lati	93%	Unknown Race 0%
Unknown Ethnicity	5%	
Hispanic or Latino	2%	







Figure 1e. Demographics Among White Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
48,010	1	90	58	24









Figure 1f. Demographics Among Unknown Race or Unknown Ethnicity Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
9,650	1	90	49	25








Figure 1g. Demographics Among Hispanic/Latino Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
11,280	1	90	42	26

Sex		Race	
Male	50%	White	63%
Female	50%	Unknown Race	33%
Unknown	0%	Black or African Ar	m 3%
		American Indian or	or 1%
Ethnicity		Asian	0%
Hispanic or Latin	o 100%	Native Hawaiian or	or 0%
Not Hispanic or L	_ati 0%		
Unknown Ethnici	ty 0%		







Figure 1h. Demographics Among Non-Hispanic/Latino Patients Hospitalized with COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
57,720	1	90	58	23








Figure 2a. Demographics Among Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,460	17	90	68	15






Figure 2b. Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021

*Cohort was too small so detailed information cannot be displayed.






Figure 2c. Demographics Among Asian Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021

Total PatientsMinimum AgeMaximum AgeMean AgeStandard Deviation5019906419








Figure 2d. Demographics Among Black or African American Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021




Standard Deviation	Mean Age	Maximum Age	Minimum Age	Total Patients
15	65	90	19	290









Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,010	19	90	70	15







Figure 2f. Demographics Among Unknown Race or Unknown Ethnicity Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
180	17	90	66	14







Figure 2g. Demographics Among Hispanic/Latino Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
190	19	90	64	18


Sex		Race	
Male	52%	White 52%	
Female	52%	Unknown Race 47%	
Unknown	0%	Asian 5%	
		Black or African Am 5%	
Ethnicity		American Indian or 0%	
Hispanic or Latin	no 100%	Native Hawaiian or 0%	
Not Hispanic or l	Lati 0%		
Unknown Ethnici	ity 0%		



Figure 2h. Demographics Among Non-Hispanic/Latino Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,220	19	90	69	15








Figure 3a. Demographics Among Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
11,770	1	90	62	20








Figure 3b. Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
90	7	90	59	16









Figure 3c. Demographics Among Asian Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
390	1	90	65	20










Figure 3d. Demographics Among Black or African American Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
2,340	1	90	58	20










Standard Deviation	Mean Age	Maximum Age	Minimum Age	Total Patients
19	64	90	1	7,920









Figure 3f. Demographics Among Unknown Race or Unknown Ethnicity Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021

Standard Deviation	Mean Age	Maximum Age	Minimum Age	Total Patients
21	58	90	1	2,030








Figure 3g. Demographics Among Hispanic/Latino Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,420	1	90	54	21

Sex		Race
Male	63%	White 62%
Female	36%	Unknown Race 34%
Jnknown	1%	Black or African Am 2%
		Asian 1%
thnicity		American Indian or 1%
lispanic or Latir	no 100%	Native Hawaiian or 0%
lot Hispanic or I	Lati 0%	
Jnknown Ethnici	ity 0%	







Figure 3h. Demographics Among Non-Hispanic/Latino Patients with Severe COVID-19 from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
9,120	1	90	63	19








Figure 4a. Demographics Among Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
230	21	90	68	14






Figure 4b. Demographics Among American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021

*Cohort was too small so detailed information cannot be displayed.







Figure 4c. Demographics Among Asian Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021	il 30, 2021
--	-------------

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
20	22	90	65	16

Sex		Race	
Male	100%	Asian	100%
Female	50%	American Indian or	0%
Unknown	0%	Black or African Am	0%
mate in the		White	0%
Ethnicity		Native Hawaiian or	0%
Not Hispanic or	Lati 100%	Unknown Race	0%
Hispanic or Latir	0%		
Unknown Ethnici	ity 0%		




Figure 4d. Demographics Among Black or African American Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021



Patients 90 and Older: 1

tion	Standard Devi	Mean Age	Maximum Age	Minimum Age	Total Patients
14		63	90	30	40








Figure 4e. Demographics Among White Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021


Patients 90 and Older: 10

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
150	21	90	70	14


Sex		Race	
Male	60%	White	100%
Female	40%	American Indian or	0%
Unknown	0%	Asian	0%
		Black or African Am	0%
Ethnicity		Native Hawaiian or	0%
Not Hispanic or Lati	86%	Unknown Race	0%
Hispanic or Latino	13%		
Unknown Ethnicity	6%		




Figure 4f. Demographics Among Unknown Race or Unknown Ethnicity Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
40	36	90	69	12










Patients 90 and Older: 2

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
40	21	90	66	14

Sex		Race
Male	75%	White 50%
Female	50%	Unknown Race 50%
Jnknown	0%	American Indian or 25%
		Asian 0%
thnicity		Black or African Am 0%
lispanic or Latin	no 100%	Native Hawaiian or 0%
Not Hispanic or L	Lati 0%	
Unknown Ethnici	ty 0%	



Figure 4h. Demographics Among Non-Hispanic/Latino Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 - April 30, 2021



Patients 90 and Older: 10

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
180	22	90	69	14

Sex		Race
Male	61%	White 72%
emale	39%	Black or African Am 16%
Inknown	0%	Asian 11%
		Unknown Race 5%
thnicity		American Indian or 0%
lot Hispanic or L	.ati 100%	Native Hawaiian or 0%
Hispanic or Latin	o 0%	
Unknown Ethnici	ty 0%	






Figure 5a. Geographic Distribution of Patients Hospitalized with COVID-19 from January 1, 2021 to April 30, 2021, by Race/Ethnicity






Figure 5b. Geographic Distribution of Patients Hospitalized with COVID-19 and a History of Vaccination from January 1, 2021 to April 30, 2021, by Race/Ethnicity






Figure 5c. Geographic Distribution of Patients with Severe COVID-19 from January 1, 2021 to April 30, 2021, by Race/Ethnicity






Figure 5d. Geographic Distribution of Patients with Severe COVID-19 and a History of Vaccination from January 1, 2021 to April 30, 2021, by Race/Ethnicity



		Code		
Code	Description	Category	Code Type	Filter
	COVID-19			
U07.1	COVID-19	Diagnosis	ICD-10-CM	n/a
9088	SARS coronavirus 2 and related RNA [presence]		TNX:LAB	Positive
	Hospitalization			
1013659	Hospital Inpatient Services	Procedure	CPT	n/a
1013699	Initial Inpatient Consultation Services	Procedure	CPT	n/a
1013729	Critical Care Services	Procedure	CPT	n/a
	Inpatient Encounter	Visit	Visit	n/a
	Inpatient Acute	Visit	Visit	n/a
	Inpatient Non-acute	Visit	Visit	n/a
	Short Stay	Visit	Visit	n/a
	COVID-19 Vaccination			
213	SARS-CoV-2 (COVID-19) Vaccine	Medication	RxNorm	n/a
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30			
	mcg/0.3mL dosage, diluent reconstituted, for intramuscular use			
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100			
	mcg/0.5mL dosage, for intramuscular use			
91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus			
	Oxford 1 (ChAdOx1) vector, preservative free, 5x10^10 viral particles/0.5mL			
	dosage, for intramuscular use			
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26)			
	vector, preservative free, 5x10^10 viral particles/0.5mL dosage, for			
	intramuscular use			
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30			
	mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use			
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50			
	mcg/0.25 mL dosage, for intramuscular use			
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus	Procedure	СРТ	n/a
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10			
	mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for			
	intramuscular use			
XW013S6	Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue,	Procedure	ICD-10-PCS	n/a
	Percutaneous Approach, New Technology Group 6			



		Code		
Code	Description	Category	Code Type	Filter
XW013T6	Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue,	Procedure	ICD-10-PCS	n/a
	Percutaneous Approach, New Technology Group 6			
XW013U6	Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous	Procedure	ICD-10-PCS	n/a
	Approach, New Technology Group 6			
XW023S6	Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous	Procedure	ICD-10-PCS	n/a
	Approach, New Technology Group 6			
XW023T6	Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous	Procedure	ICD-10-PCS	n/a
	Approach, New Technology Group 6			
XW023U6	Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New	Procedure	ICD-10-PCS	n/a
	Technology Group 6			
840534001	Administration of SARS-CoV-2 antigen vaccine	Procedure	CPT	n/a
	Severe COVID-19			
	Intensive Care Unit (ICU)			
G0390	Trauma response team associated with hospital critical care service	Procedure	HCPCS	n/a
G0509	Telehealth consultation, critical care, subsequent, physicians typically spend	Procedure	HCPCS	n/a
	50 minutes communicating with the patient and providers via telehealth			
G0508	Telehealth consultation, critical care, initial, physicians typically spend 60	Procedure	HCPCS	n/a
	minutes communicating with the patient and providers via telehealth			
99485	Supervision by a control physician of interfacility transport care of the	Procedure	СРТ	n/a
JJ+0J	critically ill or critically injured pediatric patient, 24 months of age or	Trocedure	CIT	Π/a
	younger, includes two-way communication with transport team before			
	transport, at the referring facility and during the transport, including data			
	interpretation and report; first 30 minutes			
99486	Supervision by a control physician of interfacility transport care of the	Procedure	СРТ	n/a
	critically ill or critically injured pediatric patient, 24 months of age or		5	, u
	younger, includes two-way communication with transport team before			
	transport, at the referring facility and during the transport, including data			
	interpretation and report; each additional 30 minutes (List separately in			
	addition to code for primary procedure)			
99478	Subsequent intensive care, per day, for the evaluation and management of	Procedure	СРТ	n/a
=1	the recovering very low birth weight infant (present body weight less than			/
	1500 grams)			
99479	Subsequent intensive care, per day, for the evaluation and management of	Procedure	CPT	n/a
	the recovering low birth weight infant (present body weight of 1500-2500	_		
	grams)			
99480	grams) Subsequent intensive care, per day, for the evaluation and management of	Procedure	СРТ	n/a



		Code		
Code	Description	Category	Code Type	Filter
9472	Subsequent inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 29 days through 24 months of age	Procedure	СРТ	n/a
9476	Subsequent inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 2 through 5 years of age	Procedure	СРТ	n/a
9469	Subsequent inpatient neonatal critical care, per day, for the evaluation and management of a critically ill neonate, 28 days of age or younger	Procedure	СРТ	n/a
188T	Remote real-time interactive video-conferenced critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes	Procedure	СРТ	n/a
189T	Remote real-time interactive video-conferenced critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)	Procedure	СРТ	n/a
9471	Initial inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 29 days through 24 months of age	Procedure	СРТ	n/a
9475	Initial inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 2 through 5 years of age	Procedure	СРТ	n/a
9468	Initial inpatient neonatal critical care, per day, for the evaluation and management of a critically ill neonate, 28 days of age or younger	Procedure	СРТ	n/a
9477	Initial hospital care, per day, for the evaluation and management of the neonate, 28 days of age or younger, who requires intensive observation, frequent interventions, and other intensive care services	Procedure	СРТ	n/a
9291	Critical care, evaluation and management of the critically ill or critically in injured patient; first 30-74 minutes	Procedure	СРТ	n/a
9292	Critical care, evaluation and management of the critically ill or critically in injured patient; each additional 30 minutes (List separately in addition to code for primary service)	Procedure	СРТ	n/a
9466	Critical care face-to-face services, during an interfacility transport of critically ill or critically injured pediatric patient, 24 months of age or younger; first 30- 74 minutes of hands-on care during transport		СРТ	n/a
9467	Critical care face-to-face services, during an interfacility transport of critically ill or critically injured pediatric patient, 24 months of age or younger; each additional 30 minutes (List separately in addition to code for primary service)		СРТ	n/a

Extracorporeal Membrane Oxygenation (ECMO)



		Code		
Code	Description	Category	Code Type	Filter
3989	Removal of left heart vent by thoracic incision (eg, sternotomy, thoracotomy) for ECMO/ECLS	Procedure	СРТ	n/a
3988	Insertion of left heart vent by thoracic incision (eg, sternotomy, thoracotomy) for ECMO/ECLS	Procedure	СРТ	n/a
33957	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
33958	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), percutaneous, 6 years and older (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
33959	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
33962	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition peripheral (arterial and/or venous) cannula(e), open, 6 years and older (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
33963	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition of central cannula(e) by sternotomy or thoracotomy, birth through 5 years of age (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
33964	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; reposition central cannula(e) by sternotomy or thoracotomy, 6 years and older (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
3965	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age	Procedure	СРТ	n/a
33966	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), percutaneous, 6 years and older	Procedure	СРТ	n/a
33969	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age	Procedure	СРТ	n/a
33984	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of peripheral (arterial and/or venous) cannula(e), open, 6 years and older	Procedure	СРТ	n/a



		Code		
ode	Description	Category	Code Type	Filter
3985	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of central cannula(e) by sternotomy or thoracotomy, birth through 5 years of age	Procedure	СРТ	n/a
3986	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; removal of central cannula(e) by sternotomy or thoracotomy, 6 years and older	Procedure	СРТ	n/a
3951	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), percutaneous, birth through 5 years of age (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
3952	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), percutaneous, 6 years and older (includes fluoroscopic guidance, when performed)	Procedure	СРТ	n/a
3953	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), open, birth through 5 years of age	Procedure	СРТ	n/a
3954	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of peripheral (arterial and/or venous) cannula(e), open, 6 years and older	Procedure	СРТ	n/a
3955	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of central cannula(e) by sternotomy or thoracotomy, birth through 5 years of age	Procedure	СРТ	n/a
3956	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; insertion of central cannula(e) by sternotomy or thoracotomy, 6 years and older	Procedure	СРТ	n/a
3946	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; initiation, veno-venous	Procedure	СРТ	n/a
3947	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; initiation, veno-arterial	Procedure	СРТ	n/a
3948	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; daily management, each day, veno-venous	Procedure	СРТ	n/a
3949	Extracorporeal membrane oxygenation (ECMO)/extracorporeal life support (ECLS) provided by physician; daily management, each day, veno-arterial	Procedure	СРТ	n/a
3987	Arterial exposure with creation of graft conduit (eg, chimney graft) to facilitate arterial perfusion for ECMO/ECLS (List separately in addition to code for primary procedure)	Procedure	СРТ	n/a
A15223	Extracorporeal Membrane Oxygenation, Continuous	Procedure	ICD-10-PCS	n/a
A1522F	Extracorporeal Oxygenation, Membrane, Central	Procedure	ICD-10-PCS	n/a



		Code		
Code	Description	Category	Code Type	Filter
A1522G	Extracorporeal Oxygenation, Membrane, Peripheral Veno-arterial	Procedure	ICD-10-PCS	n/a
A1522H	Extracorporeal Oxygenation, Membrane, Peripheral Veno-venous	Procedure	ICD-10-PCS	n/a
5A15A2F	Extracorporeal Oxygenation, Membrane, Central, Intraoperative	Procedure	ICD-10-PCS	n/a
5A15A2G	Extracorporeal Oxygenation, Membrane, Peripheral Veno-arterial, Intraoperative	Procedure	ICD-10-PCS	n/a
5A15A2H	Extracorporeal Oxygenation, Membrane, Peripheral Veno-venous, Intraoperative	Procedure	ICD-10-PCS	n/a
	Mechanical Ventilation			
31500	Intubation, endotracheal, emergency procedure	Procedure	CPT	n/a
40396	ALS specialized service disposable supplies; esophageal intubation	Procedure	HCPCS	n/a
94004	Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; nursing facility, per day	Procedure	СРТ	n/a
94002	Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital inpatient/observation, initial day	Procedure	СРТ	n/a
94003	Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital inpatient/observation, each subsequent day	Procedure	СРТ	n/a
4483	Moisture exchanger, disposable, for use with invasive mechanical ventilation	Procedure	HCPCS	n/a
E0481	Intrapulmonary percussive ventilation system and related accessories	Procedure	HCPCS	n/a
94662	Continuous negative pressure ventilation (CNP), initiation and management	Procedure	СРТ	n/a
9HN7BZ	Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	n/a
)9HN8BZ	Insertion of Airway into Nasopharynx, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS	n/a
)BH13EZ	Insertion of Endotracheal Airway into Trachea, Percutaneous Approach	Procedure	ICD-10-PCS	n/a
)BH17EZ	Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	n/a
)BH18EZ	Insertion of Endotracheal Airway into Trachea, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS	n/a
CHY7BZ	Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	n/a
OCHY8BZ	Insertion of Airway into Mouth and Throat, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS	n/a
DH57BZ	Insertion of Airway into Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	n/a
DH58BZ	Insertion of Airway into Esophagus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS	n/a



		Code		
Code	Description	Category	Code Type	Filter
0WHQ73Z	Insertion of Infusion Device into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	n/a
0WHQ7YZ	Insertion of Other Device into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS	n/a
5A09357	Assistance with Respiratory Ventilation, Less than 24 Consecutive Hours, Continuous Positive Airway Pressure	Procedure	ICD-10-PCS	n/a
5A09457	Assistance with Respiratory Ventilation, 24-96 Consecutive Hours, Continuous Positive Airway Pressure	Procedure	ICD-10-PCS	n/a
5A09557	Assistance with Respiratory Ventilation, Greater than 96 Consecutive Hours, Continuous Positive Airway Pressure	Procedure	ICD-10-PCS	n/a
5A1935Z	Respiratory Ventilation, Less than 24 Consecutive Hours	Procedure	ICD-10-PCS	n/a
5A1945Z	Respiratory Ventilation, 24-96 Consecutive Hours	Procedure	ICD-10-PCS	n/a
5A1955Z	Respiratory Ventilation, Greater than 96 Consecutive Hours	Procedure	ICD-10-PCS	n/a



Appendix B. List of Healthcare Common Procedure Coding System (HCPCS) and International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) Procedure Codes, and RxNorm Medication Codes Used to Define Outcomes in this Request

	Description	Code	0 - d - 7	F ! k =
Code	Description	Category	Code Type	Filter
2204740	Remdesivir	Madiaatian	Dullaria	n la
2284718	Remdesivir	Medication		n/a
XW033E5	Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS	n/a
XW043E5	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS	n/a
	Systemic Glucocorticoids			
8640	Prednisone	Medication	RxNorm	n/a
3264	Dexamethasone	Medication	RxNorm	Unknown, oral, & injectable
6902	Methylprednisolone	Medication	RxNorm	Unknown, oral, & injectable
8638	Prednisolone	Medication	RxNorm	Unknown, oral, & injectable
1514	Betamethasone	Medication	RxNorm	Oral & injectable
2878	Cortisone	Medication	RxNorm	
41126	Fluticasone	Medication	RxNorm	
25255	Formoterol	Medication	RxNorm	
5492	Hydrocortisone	Medication	RxNorm	Oral & injectable
108118	Mometasone	Medication	RxNorm	
10759	Triamcinolone	Medication	RxNorm	Oral & injectable
	Baricitinib			
2047232	Baricitinib	Medication	RxNorm	n/a
XW0DXM6	Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6	Procedure	ICD-10-PCS	n/a
XW0G7M6	Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6	Procedure	ICD-10-PCS	n/a
XW0H7M6	Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6	Procedure	ICD-10-PCS	n/a
	COVID-19 Convalescent Plasma			
XW13325	Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS	n/a
XW14325	Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS	n/a
	IL-1 Inhibitors			
72435	Anakinra	Medication	RxNorm	n/a
853491	Canakinumab	Medication	RxNorm	n/a
	Tocilizumab			
612864	Tocilizumab	Medication	RxNorm	n/a



Appendix B. List of Healthcare Common Procedure Coding System (HCPCS) and International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) Procedure Codes, and RxNorm Medication Codes Used to Define Outcomes in this Request

	_	Code		
Code	Description Bamlanivimab	Category	Code Type	Filter
				1
2463114	Bamlanivimab	Medication	RxNorm	n/a
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	Procedure	HCPCS	n/a
Q0239	Injection, bamlanivimab-xxxx, 700 mg	Procedure	HCPCS	n/a
XW033F6	Introduction of bamlanivimab monoclonal antibody into peripheral	Procedure	ICD-10-PCS	n/a
	vein, percutaneous approach, new technology group 6			
XW043F6	Introduction of bamlanivimab monoclonal antibody into central vein,	Procedure	ICD-10-PCS	n/a
	percutaneous approach, new technology group 6			
	Bamlanivimab/Etesevimab			
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion	Procedure	HCPCS	n/a
	and post administration monitoring			
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	Procedure	HCPCS	n/a
	Casirivimab/Imdevimab			
2465242	Casirivimab	Medication	RxNorm	n/a
2465249	Imdevimab	Medication	RxNorm	n/a
M0243	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	Procedure	HCPCS	n/a
Q0243	Injection, casirivimab and imdevimab, 2400 mg	Procedure	HCPCS	n/a
M0244	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency	Procedure	HCPCS	n/a
	Sotrovimab			

2550731SotrovimabMedicationRxNormn/aM0247Intravenous infusion, sotrovimab, includes infusion and post administration monitoringProcedureHCPCSn/aQ0247Injection, sotrovimab, 500 mgHCPCSn/a	Sotrovimab						
administration monitoring	2550731	Sotrovimab	Medication	RxNorm	n/a		
Q0247 Injection, sotrovimab, 500 mg HCPCS n/a	M0247		Procedure	HCPCS	n/a		
	Q0247	Injection, sotrovimab, 500 mg		HCPCS	n/a		



	Overall	American Indian or Alaska Nati	ve, or Native Hawaiian or Other Pacific Islander		Asian
Cohort 1a: Hospitalized with CO	VID - Overall	Cohort 1b: Hospitalized with CC Native Hawaiian/Other Pacific	DVID - American Indian/Alaska Native, or slander	Cohort 1c: Hospitalized with C	COVID - Asian
Group 1:	Time Restrictions	Ungrouped Terms:		Ungrouped Terms:	
Subgroup 1A:		Must Have:		Must Have:	
Must Have :		American Indian/Alaska Native (DR Native Hawaiian/Other Pacific Islander	Asian	
Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Group 1:	Time Restrictions	Group 1:	Time Restrictions
AND Subgroup 1B:		Subgroup 1A:		Subgroup 1A:	
Must Have :		Must Have :		Must Have :	
Hospitalization	[-3, 3] from Any Instance of COVID (1A)	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021
Cohort 2a: Hospitalized with CO	VID and Vaccine - Overall	AND Subgroup 1B:		AND Subgroup 1B:	
Group 1:	Time Restrictions	Must Have :		Must Have :	
Subgroup 1A:		Hospitalization	[-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)
Must Have :		Cohort 2b: Hospitalized with CC Native, or Native Hawaiian/Oth	OVID and Vaccine - American Indian/Alaska Ner Pacific Islander	Cohort 2c: Hospitalized with C	OVID and Vaccine - Asian
Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Ungrouped Terms:		Ungrouped Terms:	
AND Subgroup 1B:		Must Have:		Must Have:	
Must Have :		American Indian/Alaska Native (DR Native Hawaiian/Other Pacific Islander	Asian	
Hospitalization	[-3, 3] from Any Instance of COVID (1A)	Group 1:	Time Restrictions	Group 1:	Time Restrictions
Group 2:	Time Restrictions	Subgroup 1A:		Subgroup 1A:	
Subgroup 2A:		Must Have :		Must Have :	
Must Have :		Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021
Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	AND Subgroup 1B:		AND Subgroup 1B:	
AND Subgroup 2B:		Must Have :		Must Have :	
Must Have :		Hospitalization	[-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	Group 2:	Time Restrictions	Group 2:	Time Restrictions
Cohort 3a: Severe COVID - Overa		Subgroup 2A:		Subgroup 2A:	
Group 1:	Time Restrictions	Must Have :		Must Have :	
Subgroup 1A:		Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021
Must Have :		AND Subgroup 2B:		AND Subgroup 2B:	



	Overall	American Indian or Alaska Nati	ve, or Native Hawaiian or Other Pacific Islander		Asian
Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Must Have :		Must Have :	
U07.1 COVID diagnosis					
AND Subgroup 1B:		COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)
Must Have :			erican Indian/Alaska Native, or Native	Cohort 3c: Severe COVID - Asi	an
ICU or ECMO or Mechanical	[0, 7] days after Any Instance of COVID (1A)	Hawaiian/Other Pacific Islande Ungrouped Terms:	r	Ungrouped Terms:	
Ventilation	[0, 7] days after Any instance of COVID (1A)	ongrouped terms.		ongrouped remis.	
Cohort 4a: Severe COVID and V	/accine- Overall	Must Have:		Must Have:	
Group 1:	Time Restrictions	American Indian/Alaska Native	OR Native Hawaiian/Other Pacific Islander	Asian	
Subgroup 1A:		Group 1:	Time Restrictions	Group 1:	Time Restrictions
Must Have :		Subgroup 1A:		Subgroup 1A:	
Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Must Have :		Must Have :	
U07.1 COVID diagnosis AND Subgroup 1B:		Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021
		U07.1 COVID diagnosis		U07.1 COVID diagnosis	
Must Have :		AND Subgroup 1B:		AND Subgroup 1B:	
ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	Must Have :		Must Have :	
Group 2:	Time Restrictions	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)
Subgroup 2A:		Cohort 4b: Severe COVID and V	accine - American Indian/Alaska Native, or	Cohort 4c: Severe COVID and	Vaccine - Asian
		Native Hawaiian/Other Pacific	Islander		
Must Have :		Ungrouped Terms:		Ungrouped Terms:	
Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Must Have:		Must Have:	
AND Subgroup 2B:		American Indian/Alaska Native	OR Native Hawaiian/Other Pacific Islander	Asian	
Must Have :		Group 1:	Time Restrictions	Group 1:	Time Restrictions
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	Subgroup 1A:		Subgroup 1A:	
		Must Have :		Must Have :	
		Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021
		U07.1 COVID diagnosis		U07.1 COVID diagnosis	
		AND Subgroup 1B:		AND Subgroup 1B:	
		Must Have :		Must Have :	
		ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)
		Group 2:	Time Restrictions	Group 2:	Time Restrictions
		Subgroup 2A:		Subgroup 2A:	
		Must Have :		Must Have :	
		Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021
		U07.1 COVID diagnosis		U07.1 COVID diagnosis	



Overall

American Indian or Alaska Native, or Native Hawaiian or Other Pacific Islander

Asian

American malan of Alaska	valive, of wallve hawanan of other racine islander		Asian
AND Subgroup 2B:		AND Subgroup 2B:	
Must Have :		Must Have :	
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)



Black or African American		White	Unkr	nown Race/Ethnicity
Cohort 1d: Hospitalized with COVID - Black or African American	Cohort 1e: Hospitalized with	COVID - White	Cohort 1f: Hospitalized with COVID -	Unknown
Ungrouped Terms:	Ungrouped Terms:		Ungrouped Terms:	
Must Have:	Must Have:		Cannot Have:	
Black or African American	White		Hawaiian AND hispanic) OR (Native H	American Indian AND non-hispanic) OR (Native awaiian AND non-hispanic) OR (asian AND hispanic) :k AND hispanic) OR (black AND non-hispanic) OR non-hispanic)
Group 1: Time Restrictions	Group 1:	Time Restrictions	Group 1:	Time Restrictions
Subgroup 1A:	Subgroup 1A:		Subgroup 1A:	
Must Have :	Must Have :		Must Have :	
Positive SARS-COV-2 test OR 1/1/2021 - 4/30/2021 U07.1 COVID diagnosis	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021
AND Subgroup 1B:	AND Subgroup 1B:		AND Subgroup 1B:	
Must Have :	Must Have :		Must Have :	
Hospitalization [-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)
Cohort 2d: Hospitalized with COVID and Vaccine - Black or African American	Cohort 2e: Hospitalized with	COVID and Vaccine - White	Cohort 2f: Hospitalized with COVID a	nd Vaccine - Unknown
Ungrouped Terms:	Ungrouped Terms:		Ungrouped Terms:	
Must Have:	Must Have:		Cannot Have:	
Black or African American	White		American Indian/Alaska Native OR As Hawaiian/Other Pacific Islander OR W	ian OR Black/African American OR Native /hite OR Hispanic OR Non-Hispanic
Group 1: Time Restrictions	Group 1:	Time Restrictions	Group 1:	Time Restrictions
Subgroup 1A:	Subgroup 1A:		Subgroup 1A:	
Must Have :	Must Have :		Must Have :	
Positive SARS-COV-2 test OR 1/1/2021 - 4/30/2021 U07.1 COVID diagnosis	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021
AND Subgroup 1B:	AND Subgroup 1B:		AND Subgroup 1B:	
Must Have :	Must Have :		Must Have :	
Hospitalization [-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)
Group 2: Time Restrictions	Group 2:	Time Restrictions	Group 2:	Time Restrictions
Subgroup 2A:	Subgroup 2A:		Subgroup 2A:	
Must Have :	Must Have :		Must Have :	
Positive SARS-COV-2 test OR 1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1	1/1/2021 - 4/30/2021
U07.1 COVID diagnosis	U07.1 COVID diagnosis		COVID diagnosis	
AND Subgroup 2B:	AND Subgroup 2B:		AND Subgroup 2B:	



Blac	k or African American		White	Unk	nown Race/Ethnicity
Must Have :		Must Have :		Must Have :	
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)
Cohort 3d: Severe COVID - B	lack or African American	Cohort 3e: Severe COVID - W	/hite	Cohort 3f: Severe COVID - Unknown	
Ungrouped Terms:		Ungrouped Terms:		Ungrouped Terms:	
•• • • •					
Must Have:		Must Have:		Cannot Have:	
Black or African American		White		American Indian/Alaska Native OR As Hawaiian/Other Pacific Islander OR W	sian OR Black/African American OR Native
Group 1:	Time Restrictions	Group 1:	Time Restrictions	Group 1:	Time Restrictions
Subgroup 1A:		Subgroup 1A:		Subgroup 1A:	
Must Have :		Must Have :		Must Have :	
Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1	1/1/2021 - 4/30/2021
U07.1 COVID diagnosis	_, _, _, , ,	U07.1 COVID diagnosis	_, _, , ,	COVID diagnosis	_, _, , , ,
AND Subgroup 1B:		AND Subgroup 1B:		AND Subgroup 1B:	
Must Have :		Must Have :		Must Have :	
ICU or FCMO or Mechanical	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical	[0, 7] days after Any Instance of COVID	ICU or ECMO or Mechanical	[0, 7] days after Any Instance of COVID (1A)
Ventilation	(Ventilation	(1A)	Ventilation	
Cohort 4d: Severe COVID and	d Vaccine - Black or African American	Cohort 4e: Severe COVID and	Vaccine - White	Cohort 4f: Severe COVID and Vaccine	e - Unknown
Ungrouped Terms:		Ungrouped Terms:		Ungrouped Terms:	
Must Have:		Must Have:		Cannot Have:	
Black or African American		White		American Indian/Alaska Native OR As Hawaiian/Other Pacific Islander OR W	sian OR Black/African American OR Native
Group 1:	Time Restrictions	Group 1:	Time Restrictions	Group 1:	Time Restrictions
Subgroup 1A:		Subgroup 1A:		Subgroup 1A:	
Must Have :		Must Have :		Must Have :	
Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1	1/1/2021 - 4/30/2021
U07.1 COVID diagnosis	1/1/2021 - 1 /30/2021	U07.1 COVID diagnosis	1/1/2021 - 1 /30/2021	COVID diagnosis	1/1/2021 - 1 /J0/2021
AND Subgroup 1B:		AND Subgroup 1B:		AND Subgroup 1B:	
Must Have :		Must Have :		Must Have :	
ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)
Group 2:	Time Restrictions	Group 2:	Time Restrictions	Group 2:	Time Restrictions
Subgroup 2A:		Subgroup 2A:		Subgroup 2A:	
Must Have :		Must Have :		Must Have :	
	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1	1/1/2021 - 4/30/2021
					, ,,



Black or African American		White		Unknown Race/Ethnicity	
AND Subgroup 2B: AND Subgroup 2		AND Subgroup 2B:		AND Subgroup 2B:	
Must Have :		Must Have :		Must Have :	
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)



Hispanic		Non-Hispanic		
OVID - Hispanic	Cohort 1h: Hospitalized with COVID - Non-Hispanic			
	Ungrouped Terms:			
	Must Have:			
	Non-Hispanic			
Time Restrictions	Group 1:	Time Restrictions		
	Subgroup 1A:			
	Must Have :			
1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021		
	AND Subgroup 1B:			
	Must Have :			
[-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)		
OVID and Vaccine - Hispanic	Cohort 2h: Hospitalized with C	OVID and Vaccine - Non-Hispanic		
	Ungrouped Terms:			
	Must Have:			
	Non-Hispanic			
Time Restrictions	Group 1:	Time Restrictions		
	Subgroup 1A:			
	Must Have :			
1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021		
	AND Subgroup 1B:			
	Must Have :			
[-3, 3] from Any Instance of COVID (1A)	Hospitalization	[-3, 3] from Any Instance of COVID (1A)		
Time Restrictions	Group 2:	Time Restrictions		
	Subgroup 2A:			
	Must Have :			
1/1/2021 - 4/30/2021	<i>Must Have :</i> Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021		
	OVID - Hispanic Time Restrictions 1/1/2021 - 4/30/2021 [-3, 3] from Any Instance of COVID (1A) OVID and Vaccine - Hispanic Time Restrictions 1/1/2021 - 4/30/2021 [-3, 3] from Any Instance of COVID (1A)	OVID - Hispanic Cohort 1h: Hospitalized with C Ungrouped Terms: Must Have: Non-Hispanic Subgroup 1A: 1/1/2021 - 4/30/2021 Must Have : [-3, 3] from Any Instance of COVID (1A) Positive SARS-COV-2 test OR UO7.1 COVID diagnosis Must Have : Hospitalization Cohort 2h: Hospitalized with C Ungrouped Terms: Must Have : Hospitalization OVID and Vaccine - Hispanic Cohort 2h: Hospitalized with C Ungrouped Terms: Must Have : Non-Hispanic Cohort 2h: Hospitalized with C Ulagrouped Terms: Must Have : Non-Hispanic Cohort 2h: Hospitalized with C Ulagrouped Terms: Must Have : Non-Hispanic Subgroup 1A: Must Have : Non-Hispanic 1/1/2021 - 4/30/2021 Positive SARS-COV-2 test OR U07.1 COVID diagnosis AND Subgroup 1B: Must Have : [-3, 3] from Any Instance of COVID (1A) Hospitalization Time Restrictions Group 2:		



	Hispanic		Non-Hispanic
Must Have :		Must Have :	
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVIE (2A)
Cohort 3g: Severe COVID - Hisp	panic	Cohort 3h: Severe COVID - Non	-Hispanic
Ungrouped Terms:		Ungrouped Terms:	
Must Have:		Must Have:	
Hispanic		Non-Hispanic	
Group 1:	Time Restrictions	Group 1:	Time Restrictions
Subgroup 1A:		Subgroup 1A:	
Must Have :		Must Have :	
Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021
AND Subgroup 1B:		AND Subgroup 1B:	
Must Have :		Must Have :	
ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)
Cohort 4g: Severe COVID and \	/accine - Hispanic	Cohort 4h: Severe COVID and V	/accine - Non-Hispanic
Ungrouped Terms:		Ungrouped Terms:	
Must Have:		Must Have:	
Hispanic		Non-Hispanic	
Group 1:	Time Restrictions	Group 1:	Time Restrictions
Subgroup 1A:		Subgroup 1A:	
Must Have :		Must Have :	
Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR	1/1/2021 - 4/30/2021
U07.1 COVID diagnosis		U07.1 COVID diagnosis	
AND Subgroup 1B:		AND Subgroup 1B:	
Must Have :		Must Have :	
ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)	ICU or ECMO or Mechanical Ventilation	[0, 7] days after Any Instance of COVID (1A)
Group 2:	Time Restrictions	Group 2:	Time Restrictions
Subgroup 2A:		Subgroup 2A:	
Must Have :		Must Have :	
Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021	Positive SARS-COV-2 test OR U07.1 COVID diagnosis	1/1/2021 - 4/30/2021




	Hispanic	Non-Hispanic		
AND Subgroup 2B:		AND Subgroup 2B:		
Must Have :		Must Have :		
COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	COVID-19 vaccination	[Ever, -1] days before Any Instance of COVID (2A)	




Appendix D. Specifications Defining Analytics Modules in this Request

			_	Evaluation	Index on First Day	
#	Module	Analysis Type	Cohorts	Window	Patient Has Met:	Outcomes
1	Compare Outcomes	Measures of Association	All cohorts	0-30 days	All cohort criteria	Death
2	Compare Outcomes	Measures of Association	All cohorts	0-14 days	All cohort criteria	 Remdesivir or systemic glucocorticoids Baricitinib, COVID-19 convalescent plasma, or IL-1 inhibitors Tocilizumab Bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab






NOTE: Data obtained from the TriNetX Live® platform, aggregated from 36 health care organizations (HCOs) in the USA No Date Shift Network. Events occurring outside of a given HCO may not be captured due to the fragmented nature of electronic health care data.




<u>NOTE</u>: Data obtained from the TriNetX Live® platform, aggregated from 36 health care organizations (HCOs) in the USA No Date Shift Network. Events occurring outside of a given HCO may not be captured due to the fragmented nature of electronic health care data.





NOTE: Data obtained from the TriNetX Live® platform, aggregated from 36 health care organizations (HCOs) in the USA No Date Shift Network. Events occurring outside of a given HCO may not be captured due to the fragmented nature of electronic health care data.



<u>NOTE</u>: Data obtained from the TriNetX Live® platform, aggregated from 36 health care organizations (HCOs) in the USA No Date Shift Network. Events occurring outside of a given HCO may not be captured due to the fragmented nature of electronic health care data.